Blood test monitoring after pancreatic cancer surgery
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tracks tiny pieces of cancer DNA in your blood after pancreatic cancer surgery to see if they can predict whether cancer might come back. Researchers will draw blood several times over the next year to test this new monitoring approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 20 years old
- You have been diagnosed with pancreatic ductal adenocarcinoma (a common type of pancreatic cancer) confirmed by tissue biopsy
- You have had surgery to remove the pancreatic cancer tumor, with either clean margins or minimal residual disease
- Your recent CT or MRI scan shows no remaining tumor or spread to other organs
- You plan to receive chemotherapy (cancer drugs) after surgery
- Your surgical tumor tissue is available for genetic analysis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study looks at how your body's chemistry, immune system, and gut bacteria interact during treatment for advanced pancreatic cancer that cannot be removed by surgery. Researchers will collect blood and stool samples to analyze these factors, hoping to better understand responses to therapy.
This study looks at patients who had surgery to remove pancreatic cancer to understand what factors might lead to the cancer coming back early. If you have had surgery for pancreatic cancer and are interested in helping researchers learn more, this may be a fit.
This study looks at whether a special blood test (ctDNA) can detect tiny amounts of pancreatic cancer left after surgery. It may help doctors monitor who is at higher risk of cancer coming back, so they can tailor follow-up and treatment timing.
This trial is for people who had surgery for pancreatic cancer and are now deciding on maintenance therapy. A special blood test (ctDNA) may help doctors choose the best follow-up treatment to prevent the cancer from coming back.
This trial studies a new blood test that looks for cancer-specific immune cells after surgery for pancreatic cancer. It aims to see if the test can detect any remaining cancer cells earlier than standard methods, which could help guide further treatment decisions.
This study looks at using a special blood test (ctDNA MRD) to track how well the tumor responds to chemotherapy before surgery for pancreatic cancer. It may help doctors decide if the treatment is working and guide next steps.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.